Elacridar | 2792

Elacridar is a potent P-glycoprotein (P-gp/ABCG1) and breast cancer resistance protein (BCRP) inhibitor . GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS.

Elacridar is a potent P-glycoprotein (P-gp/ABCG1) and breast cancer resistance protein (BCRP) inhibitor . GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS.

2792 | Elacridar DataSheet

Alternate Name/Synonyms: N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide;GF120918; GG 918; GW0918; GF-120918)

Appearance: Yellow solid

Formulation: N/A

CAS Number: 143664-11-3

Structure Available?: Y

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₄H₃₃N₃O₅

Molecular Weight: 563.64

Cell-Permeable?: Y

Purity: ≥98% by HPLC

Solubilities: DMSO (~ 2 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent P-glycoprotein (P-gp/ABCG1) and breast cancer resistance protein (BCRP) inhibitor

MDL Number: MFCD00912604

PubChem CID: 119373

SMILES: COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC

InChi: InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

InChi Key: OSFCMRGOZNQUSW-UHFFFAOYSA-N